FDA data · updated 2026-09-23

Which peptide drugs are in FDA shortage right now?

As of 2026-09-23, the FDA lists 12 peptide drugs across 39 shortage records: 14 with a current shortage and 25 marked to be discontinued.

Peptide drugs affected

Current shortages

To be discontinued

Available presentations

Limited presentations

Unavailable presentations

Why these drugs are in shortage

Causes as stated by the FDA. The agency records a reason for 7 of the 39 peptide records below.

Requirements related to complying with good manufacturing practices	3
Delay in shipping of the drug	2
Discontinuation of the manufacture of the drug	2

GLP-1 and metabolic peptides

The class where shortage status has driven most compounding litigation and FDA enforcement.

Semaglutide

3 record(s): 0 current, 3 to be discontinued · availability not stated

To be discontinued
RYBELSUS
first posted 06/04/2026 · updated 06/04/2026 · (New) · discontinued 06/04/2026
FDA guidance: Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic® (semaglutide) tablets.
PresentationRybelsus®, Tablet, 3 mg (NDC 0169-4303-30)
Dosage formTablet
RouteORAL
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk Pharmaceutical Industries, LP
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-4303-30
Product NDC0169-4303
Active substanceSEMAGLUTIDE
UNII53AXN4NNHX
RxCUI2200644
FDA applicationNDA213051
Contact833-493-4689
FDA labelView FDA label
To be discontinued
RYBELSUS
first posted 06/04/2026 · updated 06/04/2026 · (New) · discontinued 06/04/2026
FDA guidance: Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic® (semaglutide) tablets.
PresentationRybelsus®, Tablet, 7 mg (NDC 0169-4307-30)
Dosage formTablet
RouteORAL
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk Pharmaceutical Industries, LP
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-4307-30
Product NDC0169-4307
Active substanceSEMAGLUTIDE
UNII53AXN4NNHX
RxCUI2200644
FDA applicationNDA213051
Contact833-493-4689
FDA labelView FDA label
To be discontinued
RYBELSUS
first posted 06/04/2026 · updated 06/04/2026 · (New) · discontinued 06/04/2026
FDA guidance: Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic® (semaglutide) tablets.
PresentationRybelsus®, Tablet, 14 mg (NDC 0169-4314-30)
Dosage formTablet
RouteORAL
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk Pharmaceutical Industries, LP
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-4314-30
Product NDC0169-4314
Active substanceSEMAGLUTIDE
UNII53AXN4NNHX
RxCUI2200644
FDA applicationNDA213051
Contact833-493-4689
FDA labelView FDA label

Liraglutide

11 record(s): 9 current, 2 to be discontinued · 6 available, 3 limited

Current shortage Available
LIRAGLUTIDE
first posted 07/18/2023 · updated 09/18/2026 · (Reverified)
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyHikma Pharmaceuticals USA, Inc.
ManufacturerHikma Pharmaceuticals USA Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0143-9144-02
Product NDC0143-9144
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationANDA215503
Contact800-631-2174
FDA labelView FDA label
Current shortage Available
LIRAGLUTIDE
first posted 07/18/2023 · updated 09/18/2026 · (Reverified)
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyHikma Pharmaceuticals USA, Inc.
ManufacturerHikma Pharmaceuticals USA Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0143-9144-03
Product NDC0143-9144
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationANDA215503
Contact800-631-2174
FDA labelView FDA label
Current shortage Available
LIRAGLUTIDE
first posted 07/18/2023 · updated 08/27/2026 · (Revised)
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyMeitheal Pharmaceuticals, Inc.
ManufacturerMeitheal Pharmaceuticals Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC71288-563-84
Product NDC71288-563
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationANDA218115
Contact844-824-8426
FDA labelView FDA label
Current shortage Available
LIRAGLUTIDE
first posted 07/18/2023 · updated 08/27/2026 · (Revised)
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyMeitheal Pharmaceuticals, Inc.
ManufacturerMeitheal Pharmaceuticals Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC71288-563-85
Product NDC71288-563
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationANDA218115
Contact844-824-8426
FDA labelView FDA label
To be discontinued
SAXENDA
first posted 08/25/2026 · updated 08/25/2026 · (New) · discontinued 08/25/2026
FDA guidance: Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
PresentationSaxenda®, Injection, 6 mg/1 mL (NDC 0169-2800-15)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk Pharmaceutical Industries, LP
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-2800-15
Product NDC0169-2800
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI1598268
FDA applicationNDA206321
Contact833-493-4689
FDA labelView FDA label
Current shortage Limited availability
VICTOZA
first posted 07/18/2023 · updated 08/25/2026 · (Revised)
FDA-stated reason: Delay in shipping of the drug
FDA guidance: Estimated shortage duration: TBD
PresentationVictoza®, Injection, 6 mg/1 mL (NDC 0169-4060-13)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-4060-13
Product NDC0169-4060
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationNDA022341
Contact833-493-4689
FDA labelView FDA label
Current shortage Available
LIRAGLUTIDE
first posted 07/18/2023 · updated 08/25/2026 · (Revised)
FDA guidance: Distributed by Teva
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerTeva Pharmaceuticals USA, Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0480-3667-20
Product NDC0480-3667
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationNDA022341
Contact833-493-4689
FDA labelView FDA label
Current shortage Available
LIRAGLUTIDE
first posted 07/18/2023 · updated 08/25/2026 · (Revised)
FDA guidance: Distributed by Teva
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerTeva Pharmaceuticals USA, Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0480-3667-22
Product NDC0480-3667
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationNDA022341
Contact833-493-4689
FDA labelView FDA label
Current shortage Limited availability
SAXENDA
first posted 07/18/2023 · updated 08/25/2026 · (Revised)
FDA-stated reason: Discontinuation of the manufacture of the drug
FDA guidance: Product will be available until discontinuation in January 2027 More from FDA
PresentationSaxenda®, Injection, 6 mg/1 mL (NDC 0169-2800-15)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk Pharmaceutical Industries, LP
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-2800-15
Product NDC0169-2800
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI1598268
FDA applicationNDA206321
Contact833-493-4689
FDA labelView FDA label
Current shortage Limited availability
VICTOZA
first posted 07/18/2023 · updated 08/17/2026 · (Revised)
FDA-stated reason: Delay in shipping of the drug
FDA guidance: Estimated shortage duration: TBD
PresentationVictoza®, Injection, 6 mg/1 mL (NDC 0169-4060-12)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0169-4060-12
Product NDC0169-4060
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI897122
FDA applicationNDA022341
Contact833-493-4689
FDA labelView FDA label
To be discontinued
LIRAGLUTIDE
first posted 05/14/2026 · updated 05/14/2026 · (New) · discontinued 05/14/2026
FDA guidance: Discontinuation of the manufacture of the drug
PresentationLiraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyTeva Pharmaceuticals USA, Inc.
ManufacturerTeva Pharmaceuticals, Inc.
Therapeutic categoryEndocrinology/Metabolism
Drug classGLP-1 Receptor Agonist [EPC]
MechanismGlucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Package NDC0480-7250-46
Product NDC0480-7250
Active substanceLIRAGLUTIDE
UNII839I73S42A
RxCUI2735350
FDA applicationANDA214568
Contact888-838-2872
FDA labelView FDA label

Pramlintide

2 record(s): 0 current, 2 to be discontinued · availability not stated

To be discontinued
SYMLINPEN
first posted 10/27/2025 · updated 10/27/2025 · (New) · discontinued 10/27/2025
FDA guidance: Discontinuation of the manufacture of the drug.
PresentationSymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyAstraZeneca AB
ManufacturerAstraZeneca Pharmaceuticals LP
Therapeutic categoryEndocrinology/Metabolism
Package NDC0310-6615-02
Product NDC0310-6615
Active substancePRAMLINTIDE ACETATE
UNII726I6TE06G
RxCUI861042
FDA applicationNDA021332
Contact800-236-9933
FDA labelView FDA label
To be discontinued
SYMLINPEN
first posted 10/27/2025 · updated 10/27/2025 · (New) · discontinued 10/27/2025
FDA guidance: Discontinuation of the manufacture of the drug.
PresentationSymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyAstraZeneca AB
ManufacturerAstraZeneca Pharmaceuticals LP
Therapeutic categoryEndocrinology/Metabolism
Package NDC0310-6627-02
Product NDC0310-6627
Active substancePRAMLINTIDE ACETATE
UNII726I6TE06G
RxCUI861042
FDA applicationNDA021332
Contact800-236-9933
FDA labelView FDA label

Insulin

7 record(s): 0 current, 7 to be discontinued · availability not stated

To be discontinued
INSULIN LISPRO PROTAMINE AND INSULIN LISPRO INJECTABLE SUSPENSION MIX75/25 KWIKPEN
first posted 09/01/2026 · updated 09/01/2026 · (New) · discontinued 09/01/2026
FDA guidance: A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
PresentationHumalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyEli Lilly and Co.
ManufacturerEli Lilly and Company
Therapeutic categoryEndocrinology/Metabolism
Drug classInsulin Analog [EPC]
Package NDC0002-8233-05
Product NDC0002-8233
Active substanceINSULIN LISPRO
UNIIGFX7QIS1II
RxCUI847252
FDA applicationBLA021017
Contact800-545-5979
FDA labelView FDA label
To be discontinued
INSULIN LISPRO JUNIOR KWIKPEN
first posted 09/01/2026 · updated 09/01/2026 · (New) · discontinued 09/01/2026
FDA guidance: A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
PresentationInsulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyEli Lilly and Co.
ManufacturerEli Lilly and Company
Therapeutic categoryEndocrinology/Metabolism
Drug classInsulin Analog [EPC]
Package NDC0002-7752-05
Product NDC0002-7752
Active substanceINSULIN LISPRO
UNIIGFX7QIS1II
RxCUI242120
FDA applicationBLA020563
Contact800-545-5979
FDA labelView FDA label
To be discontinued
REZVOGLAR KWIKPEN
first posted 09/01/2026 · updated 09/01/2026 · (New) · discontinued 09/01/2026
FDA guidance: A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
PresentationRezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyEli Lilly and Co.
ManufacturerEli Lilly and Company
Therapeutic categoryEndocrinology/Metabolism
Drug classInsulin Analog [EPC]
Package NDC0002-8980-05
Product NDC0002-8980
Active substanceINSULIN GLARGINE
UNII2ZM8CX04RZ
RxCUI2589008
FDA applicationBLA761215
Contact800-545-5979
FDA labelView FDA label
To be discontinued
Insulin Glargine Injection
first posted 10/24/2025 · updated 10/24/2025 · (New) · discontinued 10/24/2025
FDA guidance: A business decision was made to discontinue manufacture of the drug.
PresentationBasaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)
Dosage formInjection
CompanyEli Lilly and Co.
Therapeutic categoryEndocrinology/Metabolism
Package NDC0002-8214-05
Contact800-545-5979
To be discontinued
LYUMJEV TEMPO PEN
first posted 10/24/2025 · updated 10/24/2025 · (New) · discontinued 10/24/2025
FDA guidance: A business decision was made to discontinue manufacture of the drug.
PresentationLyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyEli Lilly and Co.
ManufacturerEli Lilly and Company
Therapeutic categoryEndocrinology/Metabolism
Drug classInsulin Analog [EPC]
Package NDC0002-8235-99
Product NDC0002-8235
Active substanceINSULIN LISPRO
UNIIGFX7QIS1II
RxCUI2380231
FDA applicationBLA761109
Contact800-545-5979
FDA labelView FDA label
To be discontinued
LYUMJEV TEMPO PEN
first posted 10/24/2025 · updated 10/24/2025 · (New) · discontinued 10/24/2025
FDA guidance: A business decision was made to discontinue manufacture of the drug.
PresentationLyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyEli Lilly and Co.
ManufacturerEli Lilly and Company
Therapeutic categoryEndocrinology/Metabolism
Drug classInsulin Analog [EPC]
Package NDC0002-8235-05
Product NDC0002-8235
Active substanceINSULIN LISPRO
UNIIGFX7QIS1II
RxCUI2380231
FDA applicationBLA761109
Contact800-545-5979
FDA labelView FDA label
To be discontinued
HUMALOG TEMPO PEN
first posted 10/24/2025 · updated 10/24/2025 · (New) · discontinued 10/24/2025
FDA guidance: A business decision was made to discontinue manufacture of the drug.
PresentationHumalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyEli Lilly and Co.
ManufacturerEli Lilly and Company
Therapeutic categoryEndocrinology/Metabolism
Drug classInsulin Analog [EPC]
Package NDC0002-8213-05
Product NDC0002-8213
Active substanceINSULIN LISPRO
UNIIGFX7QIS1II
RxCUI242120
FDA applicationBLA020563
Contact800-545-5979
FDA labelView FDA label

Hormone and endocrine peptides

Prescription peptide hormones; shortages here push patients toward compounded or grey-market sources.

Somatropin

1 record(s): 0 current, 1 to be discontinued · availability not stated

To be discontinued
NORDITROPIN
first posted 11/14/2025 · updated 11/14/2025 · (New) · discontinued 11/14/2025
FDA guidance: Discontinuation of the manufacture of the drug
PresentationNorditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyNovo Nordisk, Inc.
ManufacturerNovo Nordisk
Therapeutic categoryEndocrinology/Metabolism
Drug classRecombinant Human Growth Hormone [EPC]
Package NDC0169-7703-21
Product NDC0169-7703
Active substanceSOMATROPIN
UNIINQX9KB6PCL
RxCUI847243
FDA applicationBLA021148
Contact833-493-4689
FDA labelView FDA label

Desmopressin

4 record(s): 4 current, 0 to be discontinued · 1 available, 3 unavailable

Current shortage Available
Desmopressin Acetate Spray
first posted 03/12/2021 · updated 09/16/2026 · (Revised)
PresentationDesmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)
Dosage formSpray
CompanyApotex Corp.
Therapeutic categoryHematology
Package NDC60505-0815-0
Contact800-706-5575
Current shortage Unavailable
Desmopressin Acetate Spray
first posted 03/12/2021 · updated 05/01/2026 · (Reverified)
FDA-stated reason: Requirements related to complying with good manufacturing practices
FDA guidance: Estimated recovery: TBD
PresentationStimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)
Dosage formSpray
CompanyFerring
Therapeutic categoryHematology
Package NDC0053-6871-00
Contact888-337-7464
Current shortage Unavailable
Desmopressin Acetate Spray
first posted 03/12/2021 · updated 05/01/2026 · (Reverified)
FDA-stated reason: Requirements related to complying with good manufacturing practices
FDA guidance: Estimated recovery: TBD
PresentationDdavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)
Dosage formSpray
CompanyFerring
Therapeutic categoryHematology
Package NDC55566-2500-0
Contact888-337-7464
Current shortage Unavailable
Desmopressin Acetate Spray
first posted 03/12/2021 · updated 05/01/2026 · (Reverified)
FDA-stated reason: Requirements related to complying with good manufacturing practices
FDA guidance: Estimated recovery: TBD
PresentationDesmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)
Dosage formSpray
CompanyFerring
Therapeutic categoryHematology
Package NDC69918-501-05
Contact888-337-7464

Other therapeutic peptides

Approved peptide drugs outside the metabolic and endocrine classes.

Icatibant

2 record(s): 0 current, 2 to be discontinued · availability not stated

To be discontinued
ICATIBANT
first posted 05/07/2026 · updated 05/07/2026 · (New) · discontinued 05/07/2026
FDA guidance: Discontinuation of the manufacturer of the drug
PresentationIcatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyFresenius Kabi USA, LLC
ManufacturerFresenius Kabi USA, LLC
Therapeutic categoryHematology
Package NDC63323-574-86
Product NDC63323-574
Active substanceICATIBANT ACETATE
UNII325O8467XK
RxCUI1148141
FDA applicationANDA208317
Contact847-550-2300
FDA labelView FDA label
To be discontinued
ICATIBANT
first posted 05/07/2026 · updated 05/07/2026 · (New) · discontinued 05/07/2026
FDA guidance: Discontinuation of the manufacturer of the drug
PresentationIcatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)
Dosage formInjection
RouteSUBCUTANEOUS
CompanyFresenius Kabi USA, LLC
ManufacturerFresenius Kabi USA, LLC
Therapeutic categoryHematology
Package NDC63323-574-93
Product NDC63323-574
Active substanceICATIBANT ACETATE
UNII325O8467XK
RxCUI1148141
FDA applicationANDA208317
Contact847-550-2300
FDA labelView FDA label

Peptide antibiotics and antifungals

Glycopeptide, lipopeptide and echinocandin drugs, peptides by structure and frequently in shortage.

Vancomycin

1 record(s): 0 current, 1 to be discontinued · availability not stated

To be discontinued
Vancomycin Hydrochloride Injection
first posted 11/14/2025 · updated 11/14/2025 · (New) · discontinued 11/14/2025
FDA guidance: Discontinuation of the manufacture of the drug
PresentationVancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)
Dosage formInjection
CompanyHospira, Inc., a Pfizer Company
Therapeutic categoryAnti-Infective
Package NDC0409-5017-01
Contact844-646-4398

Daptomycin

2 record(s): 0 current, 2 to be discontinued · availability not stated

To be discontinued
Daptomycin Injection
first posted 06/30/2026 · updated 06/30/2026 · (New) · discontinued 06/30/2026
FDA guidance: Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc.
PresentationDaptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01)
Dosage formInjection
CompanyJiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Therapeutic categoryAnti-Infective
Package NDC0143-9378-01
Contact609-395-8625 ext. 203
To be discontinued
Daptomycin Injection
first posted 06/30/2026 · updated 06/30/2026 · (New) · discontinued 06/30/2026
FDA guidance: Discontinuation of the manufacture of the drug
PresentationDaptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1)
Dosage formInjection
CompanyJiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Therapeutic categoryAnti-Infective
Package NDC57884-3151-1
Contact609-395-8625 ext. 203

Bacitracin

1 record(s): 1 current, 0 to be discontinued · 1 unavailable

Current shortage Unavailable
Bacitracin Ophthalmic Ointment
first posted 03/03/2025 · updated 06/01/2026 · (Revised)
FDA-stated reason: Discontinuation of the manufacture of the drug
FDA guidance: Shortage is estimated for 24 months
PresentationBacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)
Dosage formOphthalmic Ointment
CompanyPadagis US LLC
Therapeutic categoryAnti-Infective
Package NDC0574-4022-35
Contact866-634-9120

Caspofungin

3 record(s): 0 current, 3 to be discontinued · availability not stated

To be discontinued
CASPOFUNGIN ACETATE
first posted 06/30/2026 · updated 06/30/2026 · (New) · discontinued 06/30/2026
FDA guidance: Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
PresentationCaspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94)
Dosage formInjection
RouteINTRAVENOUS
CompanyJiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
ManufacturerSandoz Inc
Therapeutic categoryAnti-Infective
Package NDC0781-3421-94
Product NDC0781-3421
Active substanceCASPOFUNGIN ACETATE
UNIIVUW370O5QE
RxCUI828539
FDA applicationANDA200833
ContactSandoz: 800-525-8747
FDA labelView FDA label
To be discontinued
CASPOFUNGIN ACETATE
first posted 06/30/2026 · updated 06/30/2026 · (New) · discontinued 06/30/2026
FDA guidance: Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug
PresentationCaspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94)
Dosage formInjection
RouteINTRAVENOUS
CompanyJiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
ManufacturerSandoz Inc
Therapeutic categoryAnti-Infective
Package NDC0781-3423-94
Product NDC0781-3423
Active substanceCASPOFUNGIN ACETATE
UNIIVUW370O5QE
RxCUI828539
FDA applicationANDA200833
ContactSandoz: 800-525-8747
FDA labelView FDA label
To be discontinued
CASPOFUNGIN ACETATE
first posted 01/12/2026 · updated 01/12/2026 · (New) · discontinued 01/12/2026
FDA guidance: Discontinuation of the manufacture of the drug
PresentationCaspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)
Dosage formInjection
RouteINTRAVENOUS
CompanyFresenius Kabi USA, LLC
ManufacturerFresenius Kabi USA, LLC
Therapeutic categoryAnti-Infective
Package NDC63323-358-10
Product NDC63323-358
Active substanceCASPOFUNGIN ACETATE
UNIIVUW370O5QE
RxCUI828539
FDA applicationNDA206110
Contact888-386-1300
FDA labelView FDA label

Micafungin

2 record(s): 0 current, 2 to be discontinued · availability not stated

To be discontinued
Micafungin Sodium Injection
first posted 09/11/2026 · updated 09/11/2026 · (New) · discontinued 09/11/2026
FDA guidance: A business decision was made to discontinue manufacture of the drug.
PresentationMicafungin Sodium, Injection, 10 mg/1 mL (NDC 42023-229-10)
Dosage formInjection
CompanyPar Health, USA LLC
Therapeutic categoryAnti-Infective
Package NDC42023-229-10
Contact800-828-9393
To be discontinued
Micafungin Sodium Injection
first posted 09/11/2026 · updated 09/11/2026 · (New) · discontinued 09/11/2026
FDA guidance: A business decision was made to discontinue manufacture of the drug.
PresentationMicafungin Sodium, Injection, 20 mg/1 mL (NDC 42023-230-10)
Dosage formInjection
CompanyPar Health, USA LLC
Therapeutic categoryAnti-Infective
Package NDC42023-230-10
Contact800-828-9393

Why shortage status matters legally

While the FDA lists a drug as in shortage, licensed 503A pharmacies and 503B outsourcing facilities may compound copies of it. When the FDA marks the shortage resolved, that permission ends.

This is the legal basis for compounded semaglutide (not FDA-approved, not a generic of Wegovy® or Ozempic®, and not evaluated by the FDA for safety, effectiveness, or quality). A shortage list that is out of date is not just stale. It can be wrong about what is currently lawful to compound.

Frequently asked questions

Is this shortage list current?

Yes. This page reads the U.S. Food and Drug Administration drug shortage database and was last updated on 2026-09-23. The FDA updates its list continuously and this page refreshes from that source.

What is the difference between status and availability?

Status is where the product sits in the FDA shortage process: a current shortage, a product the manufacturer plans to stop making, or a resolved shortage. Availability is what supply looks like right now: available, limited, or unavailable. A product can carry a current shortage status while some presentations are still available.

What does “to be discontinued” mean?

It means the manufacturer has told the FDA it plans to stop making that specific product. It is not the same as an active current shortage.

Does a shortage make compounding legal?

While a drug is on the FDA shortage list, licensed 503A pharmacies and 503B facilities may compound copies of it under federal rules. That permission ends when the FDA marks the shortage resolved.

Why are GLP-1 drugs like semaglutide on this list?

Demand for GLP-1 medicines has been high. Shortage status for these drugs is what allowed compounded semaglutide (not FDA-approved, not a generic of Wegovy® or Ozempic®, and not evaluated by the FDA for safety, effectiveness, or quality) to be produced, so their FDA status matters for what is lawful.

Where does this data come from?

The openFDA drug shortages API, a public database published by the U.S. Food and Drug Administration. Every field shown on this page, including the stated reason, availability, revision history and product identifiers, comes directly from that source.

Source: openFDA drug shortages API, U.S. Food and Drug Administration. 1601 shortage records scanned. Last updated 2026-09-23. Do not rely on this page to make decisions regarding medical care; always speak to your health provider about the risks and benefits of FDA-regulated products.

Which peptide drugs are in FDA shortage right now?

Why these drugs are in shortage

GLP-1 and metabolic peptides

Semaglutide

Liraglutide

Pramlintide

Insulin

Hormone and endocrine peptides

Somatropin

Desmopressin

Other therapeutic peptides

Icatibant

Peptide antibiotics and antifungals

Vancomycin

Daptomycin

Bacitracin

Caspofungin

Micafungin

Why shortage status matters legally

Frequently asked questions

Is this shortage list current?

What is the difference between status and availability?

What does “to be discontinued” mean?

Does a shortage make compounding legal?

Why are GLP-1 drugs like semaglutide on this list?

Where does this data come from?

Related data